Comparing the clinical outcomes of initial surgery and primary definitive radiotherapy with a dosage of 6600 cGy or higher in cT1-2N0M0 oral cavity squamous cell carcinoma: A nationwide cohort study.
cT1−2N0M0
cancer registry
clinical outcomes
definite radiotherapy
oral cavity squamous cell carcinoma
surgery
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
May 2024
May 2024
Historique:
revised:
14
12
2023
received:
30
08
2023
accepted:
31
01
2024
medline:
21
5
2024
pubmed:
21
5
2024
entrez:
21
5
2024
Statut:
ppublish
Résumé
To compare the clinical outcomes of two treatment modalities, initial surgery and primary definitive radiotherapy (RT), in Taiwanese patients diagnosed with cT1-2N0M0 oral cavity squamous cell carcinoma (OCSCC). Between 2011 and 2019, we analyzed data for 13,542 cT1-2N0M0 patients who underwent initial surgery (n = 13,542) or definitive RT with a dosage of at least 6600 cGy (n = 145) for the treatment of OCSCC. To account for baseline differences, we employed propensity score (PS) matching, resulting in two well-balanced study groups (initial surgery, n = 580; definitive RT, n = 145). Before PS matching, the 5-year disease-specific survival (DSS) rates were 88% for the surgery group and 58% for the RT group. After PS matching, the 5-year DSS rates of the two groups were 86% and 58%, respectively. Similarly, the 5-year overall survival (OS) rates before PS matching were 80% for the surgery group and 36% for the RT group, whereas after PS matching, they were 73% and 36%, respectively. All these differences were statistically significant (p < 0.0001). A multivariable analysis identified treatment with RT, older age, stage II tumors, and a higher burden of comorbidities as independent risk factors for both DSS and OS. We also examined the 5-year outcomes for various subgroups (margin ≥5 mm, margin <5 mm, positive margins, RT combined with chemotherapy, and RT alone) as follows: DSS, 89%/88%/79%/63%/51%, respectively, p < 0.0001; OS, 82%/79%/68%/39%/32%, respectively, p < 0.0001. In Taiwanese patients with cT1-2N0M0 OCSCC, a remarkably low proportion (1.1%) completed definitive RT. A significant survival disparity of 30% was observed between patients who underwent initial surgery and those who received definitive RT. Interestingly, even patients from the surgical group with positive surgical margins exhibited a significantly superior survival compared to those in the definitive RT group.
Sections du résumé
BACKGROUND
BACKGROUND
To compare the clinical outcomes of two treatment modalities, initial surgery and primary definitive radiotherapy (RT), in Taiwanese patients diagnosed with cT1-2N0M0 oral cavity squamous cell carcinoma (OCSCC).
METHODS
METHODS
Between 2011 and 2019, we analyzed data for 13,542 cT1-2N0M0 patients who underwent initial surgery (n = 13,542) or definitive RT with a dosage of at least 6600 cGy (n = 145) for the treatment of OCSCC. To account for baseline differences, we employed propensity score (PS) matching, resulting in two well-balanced study groups (initial surgery, n = 580; definitive RT, n = 145).
RESULTS
RESULTS
Before PS matching, the 5-year disease-specific survival (DSS) rates were 88% for the surgery group and 58% for the RT group. After PS matching, the 5-year DSS rates of the two groups were 86% and 58%, respectively. Similarly, the 5-year overall survival (OS) rates before PS matching were 80% for the surgery group and 36% for the RT group, whereas after PS matching, they were 73% and 36%, respectively. All these differences were statistically significant (p < 0.0001). A multivariable analysis identified treatment with RT, older age, stage II tumors, and a higher burden of comorbidities as independent risk factors for both DSS and OS. We also examined the 5-year outcomes for various subgroups (margin ≥5 mm, margin <5 mm, positive margins, RT combined with chemotherapy, and RT alone) as follows: DSS, 89%/88%/79%/63%/51%, respectively, p < 0.0001; OS, 82%/79%/68%/39%/32%, respectively, p < 0.0001.
CONCLUSIONS
CONCLUSIONS
In Taiwanese patients with cT1-2N0M0 OCSCC, a remarkably low proportion (1.1%) completed definitive RT. A significant survival disparity of 30% was observed between patients who underwent initial surgery and those who received definitive RT. Interestingly, even patients from the surgical group with positive surgical margins exhibited a significantly superior survival compared to those in the definitive RT group.
Types de publication
Journal Article
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e7127Subventions
Organisme : Chang Gung Memorial Hospital, Linkou
ID : BMRPC55
Organisme : Chang Gung Memorial Hospital, Linkou
ID : CMRPD1H0521
Informations de copyright
© 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
National Comprehensive Cancer Network. Clinical Practice Guidelines in oncology, Head and Neck Cancers, Version I. 2024. Accessed December 10, 2023. http://www.nccn.org/
Sowder JC, Cannon RB, Buchmann LO, et al. Treatment‐related determinants of survival in early‐stage (T1‐2N0M0) oral cavity cancer: a population‐based study. Head Neck. 2017;39(5):876‐880. doi:10.1002/hed.24679
Ellis MA, Graboyes EM, Wahlquist AE, et al. Primary surgery vs radiotherapy for early stage Oral cavity cancer. Otolaryngol Head Neck Surg. 2018;158(4):649‐659.
Liu WC, Liu HE, Kao YW, et al. Definitive intensity‐modulated radiotherapy or surgery for early oral cavity squamous cell carcinoma: propensity‐score‐matched, nationwide, population‐based cohort study. Head Neck. 2021;43(4):1142‐1152. doi:10.1002/hed.26575
Chen YC, Fan KH, Lin CY, et al. Outcomes of re‐irradiation for oral cavity squamous cell carcinoma. Biom J. 2022;45(6):940‐947. doi:10.1016/j.bj.2021.12.005
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93(4):387‐391. doi:10.1038/sj.bjc.6602678
Sauerbrei W, Taube SE, McShane LM, Cavenagh MM, Altman DG. Reporting recommendations for tumor marker prognostic studies (REMARK): an abridged explanation and elaboration. J Natl Cancer Inst. 2018;110(8):803‐811. doi:10.1093/jnci/djy088
American College of Surgeons. Standards for oncology registry entry. STORE 2023. Effective for Cases Diagnosed. 2023. Accessed May 17, 2023. https://wwwfacsorg/media/vssjur3j/store_manual_2023pdf
Montgomery DC. Introduction to Statistical Quality Control. 6th ed. John Wiley & Sons; 2009.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373‐383. doi:10.1016/0021-9681(87)90171-8
Mendenhall WM, Holtzman AL, Dagan R, et al. Current role of radiotherapy in the management of oral cavity squamous cell carcinoma. Craniomaxillofac Trauma Reconstr. 2021;14(1):79‐83. doi:10.1177/1943387520971418
El‐Naaj IA, Leiser Y, Shveis M, Sabo E, Peled M. Incidence of oral cancer occult metastasis and survival of T1‐T2N0 oral cancer patients. J Oral Maxillofac Surg. 2011;69(10):2674‐2679. doi:10.1016/j.joms.2011.02.012
D'Cruz AK, Vaish R, Kapre N, et al. Head and neck disease management group. Elective versus therapeutic neck dissection in node‐negative oral cancer. N Engl J Med. 2015;373(6):521‐529. doi:10.1056/NEJMoa1506007
Massey C, Dharmarajan A, Bannuru RR, Rebeiz E. Management of N0 neck in early oral squamous cell carcinoma: a systematic review and meta‐analysis. Laryngoscope. 2019;129(8):E284‐E298. doi:10.1002/lary.27627
Chien CY, Wang CP, Lee LY, et al. Indications for elective neck dissection in cT1N0M0 oral cavity cancer according to the AJCC eight edition: a nationwide study. Oral Oncol. 2023;140:106366. doi:10.1016/j.oraloncology.2023.106366
Bernier J, Cooper JS, Pajak T, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (# 22931) and RTOG (# 9501). Head Neck. 2005;27:843‐850. doi:10.1002/hed.20279
Liao CT, Lee LY, Huang SF, et al. Outcome analysis of patients with oral cavity cancer and extracapsular spread in neck lymph nodes. Int J Radiat Oncol Biol Phys. 2011;81(4):930‐937. doi:10.1016/j.ijrobp.2010.07.1988
Liao CT, Lee LY, Lee SR, et al. Optimizing margin status for improving prognosis in patients with oral cavity squamous cell carcinoma: a retrospective study from the two highest‐volume Taiwanese hospitals. Front Oncol. 2022;12:1019555. doi:10.3389/fonc.2022
Cancer registry annual report, 2021 Taiwan. 2023. Accessed December 10, 2023. http://www.bhp.doh.gov.tw/
Chaturvedi P, Vaishampayan SS, Nair S, et al. Oral squamous cell carcinoma arising in background of oral submucous fibrosis: a clinicopathologically distinct disease. Head Neck. 2013;35(10):1404‐1409. doi:10.1002/hed.23143
Li YC, Cheng AJ, Lee LY, Huang YC, Chang JT. Multifaceted mechanisms of areca nuts in oral carcinogenesis: the molecular pathology from precancerous condition to malignant transformation. J Cancer. 2019;10(17):4054‐4062. doi:10.7150/jca.29765